Opendata, web and dolomites

Cenya SIGNED

Ex vivo cell labelling for in vivo imaging applied to cell therapeutics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Cenya project word cloud

Explore the words cloud of the Cenya project. It provides you a very rough idea of what is the project "Cenya" about.

lymphocyte    imaging    direct    good    therapy    trafficking    noninvasive    academics    medicine    possess    licensing    nps    venture    degree    day    optimisation    40    market    advisors    monitor    tissue    monitoring    car    size    modern    unbelievable    deal    cancer    ready    inhibitors    industry    push    annum    optimise    nearly    stem    hired    lack    therapeutics    tracking    drive    track    staff    expectations    preclinical    clinical    patients    hurdles    fda    ceo    safety    exclusively    trials    while    data    multiscale    cell    necessitating    gene    curing    np    diseased    techniques    simpler    gmp    decide    diagnose    bench    agents    cheaper    checkpoint    validation    repopulating    bedside    time    outlined    magic    play    opportunity    commercial    treatments    sometimes    individual    infusion    ex    lower    regulatory    disease    labelling    biodistribution    attractive    labelled    made    transferred    suitable    advent    therapies    cenya    approval    heart    faster    recruited    surveyed    vivo    fallen    investment    cells    300m    seeing    nanoparticle   

Project "Cenya" data sheet

The following table provides information about the project.

Coordinator
CENYA IMAGING B.V. 

Organization address
address: TWEEDE KOSTVERLORENKADE 11H
city: AMSTERDAM
postcode: 1052RK
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENYA IMAGING B.V. NL (AMSTERDAM) coordinator 150˙000.00

Map

 Project objective

While we do not possess magic, modern day medicine can sometimes approach the unbelievable - curing cancer or repopulating diseased heart tissue; all possible due to the advent of cell therapy. However, cell therapy has fallen far short of expectations. Its success requires the ability to monitor and optimise treatments in real time for each individual; necessitating a direct means of monitoring transferred cells. Noninvasive imaging techniques are essential to the success of modern therapeutics. Here, I will build on my work on developing multiscale GMP-ready imaging nanoparticle (NP) agents with the objective of out-licensing the technology to a new commercial venture, Cenya Imaging, to take this work from the bench to the bedside, and I have recruited an experienced CEO to drive this forward. Advisors have outlined a cheaper, faster and simpler path to regulatory approval for Cenya NPs: labelling cells ex vivo and tracking labelled cells after infusion into patients; since, with this approach, Cenya NPs are used to only track cells and not diagnose a disease, the regulatory hurdles are far lower. Recent developments in cell therapeutics have made tracking of cells a very attractive market; specifically (1) increasing investment in CAR-T cells, checkpoint inhibitors (which affect lymphocyte trafficking), and stem cell therapies (40% per annum growth in phase I trials); (2) regulatory push for increased safety and biodistribution data in trials; and (3) a lack of suitable clinical imaging agents. Market size is estimated at €300M; the FDA recently hired 50 new staff exclusively to deal with cell and gene therapies. We will exploit this new market, while also seeing this as the opportunity to play a significant role in the optimisation of cell therapies. We have surveyed nearly 100 users of cell therapy (preclinical, clinical; academics and industry) to decide on our approach, providing a good degree of validation for our choice of focus.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CENYA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CENYA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

LO-KMOF (2019)

Vapour-deposited metal-organic frameworks as high-performance gap-filling dielectrics for nanoelectronics

Read More  

TRUST (2018)

Truth and Semantics

Read More  

PLAT_ACE (2019)

A new platform technology for the on-demand access to large acenes

Read More